New KLAS Analysis report and analysis research carried out with Quest Diagnostics spotlight firm’s buyer and product momentum
Proscia®, a world chief in AI-enabled pathology options for precision drugs, has expanded its management place within the diagnostic pathology market. The corporate has grown its medical buyer base by greater than 100% previously yr. Amongst its different highlights, Proscia was acknowledged by KLAS Analysis in a June 2024 Emerging Company Spotlight report and launched findings from a study carried out with Quest Diagnostics, a number one supplier of diagnostic data providers, on the impression of its AI-enabled workflows.
Proscia’s momentum comes as digital pathology experiences a brand new surge in world demand. Laboratories are more and more in search of to increase their companies by capitalizing on the real-world knowledge generated within the shift from microscope to photographs; every entire slide picture incorporates over 1 billion pixels that may advance the following blockbuster therapies. With its Concentriq® software program platform, Proscia permits laboratories to completely leverage their knowledge whereas optimizing operations and laying the inspiration to unlock new insights with AI purposes.
KLAS Rising Firm Highlight confirms Concentriq delivers instant worth and clients belief Proscia
Early knowledge from KLAS reveals the vast majority of Proscia’s clients surveyed noticed instant advantages from Concentriq, and all such clients achieved outcomes inside 6 months of deploying the enterprise pathology platform. Impacts cited embrace enhancing turnaround instances, attracting extra expertise, and making a real-world knowledge archive for fueling analysis and growth.
The KLAS report moreover reveals that these clients are impressed with each the extent of help they obtain and Proscia’s pathology experience. Additionally they awarded Proscia an ‘A+’ ranking for its govt workforce’s involvement. Working with a trusted companion that provides a world-class software program platform has led 100% of Proscia’s clients surveyed to say they might purchase once more.
Learn KLAS Analysis’s Rising Firm Highlight on Concentriq by accessing the complete report here.
Quest Diagnostics research highlights Concentriq’s scalable method to AI
Utilizing Concentriq’s AI-enabled workflows with Ibex’s clinical-grade, AI-powered Prostate* resolution, pathologists at Quest Diagnostics have been capable of signal out 2.9 instances per hour as an alternative of 1.2. The providing was designed to help pathologists in enhancing the detection and grading of prostate most cancers by streamlining pathologists’ evaluate of tissue samples which have been scanned at excessive decision to create digital slides, or entire slide photographs (WSIs), which pathologists can then view.
The research included 180 randomized prostate instances from grownup (21 or older) topics. 100% of the pathologists who participated within the research said they might be more likely to undertake AI on the research’s conclusion. Quest Diagnostics, via its AmeriPath and Dermpath Diagnostics subspecialty pathology companies, employs over 400 pathologists at its nationwide community of medical laboratories.
“We’re thrilled to assist exhibit the impression of AI-driven pathology via this research with Proscia and Ibex Medical Analytics,” mentioned Kristie Dolan, Senior Vice President and Common Supervisor of Oncology & Pathology at Quest Diagnostics. “The findings present additional proof that pathology is present process an unprecedented transformation, and we’ll proceed to collaborate with world-class corporations to stay on the forefront of this innovation.”
View and obtain the research in its entirety here.
Latest FDA clearance permits Proscia to convey its software program to U.S. diagnostic pathology market
In February, Proscia acquired FDA 510(okay) clearance for its Concentriq AP-Dx** resolution for the aim of major prognosis. This milestone not solely opened the U.S. diagnostic pathology market to Proscia but additionally permits its distribution companions Agilent Applied sciences and Siemens Healthineers to supply its software program to their U.S.-based clients.
Proscia’s 510(okay) clearance additional builds on its regulatory credentials. It was the primary firm to obtain CE-IVDR certification to advance digital pathology major prognosis within the European Union and has merchandise licensed in Canada and cleared in the UK amongst different nations.
“An increasing number of laboratories are placing their belief in Proscia to assist them ship quicker outcomes, present assured diagnoses, and increase their companies, particularly now that we have now FDA clearance,” mentioned David West, CEO. “It’s extremely rewarding to see the impression our Concentriq platform and workforce are delivering. That is evident from the constructive suggestions our clients shared with KLAS in addition to Quest Diagnostics’ spectacular research outcomes.”
*The Ibex suite consists of options that are for Analysis Use Solely (RUO) in the US and never cleared by the FDA. A number of options are CE marked (IVDD and IVDR) and registered with the UK MHRA. For extra data, together with indication to be used and regulatory approval in different nations, contact Ibex Medical Analytics.
**Concentriq AP-Dx is cleared (K230839) for medical use with the Hamamatsu NanoZoomer S360MD Slide scanner in the US.
Join the free insideAI Information newsletter.
Be a part of us on Twitter: https://twitter.com/InsideBigData1
Be a part of us on LinkedIn: https://www.linkedin.com/company/insideainews/
Be a part of us on Fb: https://www.facebook.com/insideAINEWSNOW
